| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
2 companies
Seth Loring Harrison is Director, 10% Owner at STOK, with reported holdings spanning 2 companies. Seth Loring Harrison's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $463.2M at current prices.
Seth Loring Harrison's largest disclosed position is in STOK as Director, 10% Owner, worth about $463.2M. Net of sales, the STOK filings show accumulation of 1,763,889 shares.
Seth Loring Harrison has 14 Form 4 filings on record from June 2015 to July 2026, across 3 companies: Director at Stoke Therapeutics (STOK), 2019–2026; Director at AKRO, 2025; Director, 10% Owner at Eledon Pharmaceuticals (ELDN), 2015–2016.
The 40 reported transactions were 16 gifts, 10 option or other derivative awards, 9 dispositions back to the company and 3 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $39.6M and no sales.
The largest open-market purchase was 1,388,889 shares of STOK at an average $18.00 on June 21, 2019, about $25.0M.